Services

reMYND, a trusted research partner

Our Contract Research Organization (CRO) helps our clients assess in-vivo characteristics, pharmacokinetics, pharmacodynamics and the effects of their experimental treatments against Alzheimer's disease and other neurodegenerative diseases in our proprietary mouse models.

We serve the majority of the Top 10 pharmaco’s worldwide with clients in the US, Europe and Japan. We have provided pivotal in-vivo proof-of-concept data for several candidate drugs currently in clinical development, and work actively together with Dr. Sugimoto, the inventor of Aricept. We have helped our clients to be the first to demonstrate the synergistic effect of a BACE inhibitor and an aBeta antibody, the effect of Tau antibody on aBeta, the effect of donepezil on brain Abeta,… 

The continuous availability of aged mice allows for a short response time and rapid study start. By contributing our extensive expertise and experience we are helping our clients to set up an optimal study design. The CRO offers a broad testing window for our portfolio of behavioral readouts in combination with all routes of administration, as well as immunohistochemical and biochemical read-outs, both in brain and cerebrospinal fluid (CSF).

Aβ pathology

Tau pathology

Astrocytosis and microgliosis

Neuronal loss

Cognitive impairment

Motoric impairment

Other behavior

LTP deficit

Impaired survival

CSF Biomarker

APP[V717I]

APP[V717I]xPS1[A246E]

Tau[P301L]

Tau[P301S]

APP[V717I]xTau[P301S]

has been investigated and shown to be present

Seed and spread alpha-synuclein

A model to study the prion-like neuron to neuron transmission of Tau pathology

Read more
APP[V717I]

APP-London model for studying Alzheimer's disease. Due to the wildtype BACE-cleavage site, a preferred model for testing anti-beta-secretase and anti-gamma-secretase associated approaches

Read more
APP[V717I]xPS1[A246E]

A model for studyin gAlzheimer's Disease that develops similar charcteristics as the APP-London model but at an accelerated pace

Read more
Tau[P301L]

Tauopathy model for studying  Frontotemperal dementia and Alzheimer’s disease. Additionally, this model has been extensively used to assess experimental treatments that are currently in clinical testing.

Read more
Tau[P301S]

Tauopathy model for Frontotemperal dementia and Alzheimer’s disease.

Read more
APP[V717I]xTau[P301S]

A combined APP and Tau model for studying Alzheimer’s disease.

Read more
APP[V717I]xTau[P301L]

A combined APP and Tau model for studying Alzheimer’s disease.

Read more
Seed and spread

A model to study the prion-like neuron to neuron trans-synaptic transmission of Tau pathology

Read more